August 2023 in “International Journal of Molecular Sciences” Human skin xenografting could improve our understanding of skin development, renewal, and healing.
130 citations,
February 2018 in “Journal of Investigative Dermatology” Tofacitinib may help treat severe hair loss, but more research is needed.
49 citations,
May 2018 in “Journal of the American Academy of Dermatology” Applying 2% tofacitinib cream helped some children with severe hair loss grow back hair.
9 citations,
January 2023 in “Dermatology and therapy” A 14-year-old girl with severe hair loss regrew her hair using upadacitinib.
2 citations,
July 1998 in “International Journal of Dermatology” We need a safe, reliable way to stop severe hair loss.
November 2023 in “Indian Dermatology Online Journal” Tofacitinib was effective for severe, treatment-resistant hair loss without side effects.
January 2021 in “The Ochsner journal” ADHD stimulant medications might be linked to a specific type of hair loss called Alopecia Universalis.
COVID-19 may trigger or worsen rapid hair loss in alopecia areata.
18 citations,
April 2010 in “Archives of Dermatology” Psoriasis or contact dermatitis can override alopecia areata, allowing hair growth.
October 2023 in “Frontiers in Medicine” Dupilumab helped a 4-year-old grow hair back after another treatment failed.
January 2018 in “Springer eBooks” Alopecia totalis/universalis is a severe form of hair loss where all body hair is lost.
185 citations,
June 2014 in “Journal of Investigative Dermatology” A man with severe hair loss and skin disease regrew his hair with no side effects after taking tofacitinib.
182 citations,
October 2003 in “British Journal of Dermatology” The 2003 guidelines suggest that while some treatments can regrow hair in alopecia areata, none alter the disease's progression, and wigs may be the best option for extensive hair loss.
117 citations,
February 1996 in “International Journal of Dermatology” A 300 mg monthly pulse of prednisolone effectively and safely treats widespread alopecia areata.
104 citations,
March 1987 in “Journal of The American Academy of Dermatology” Minoxidil helps hair growth in 63.6% of alopecia patients, with 27.3% having excellent results.
96 citations,
December 2015 in “JAMA dermatology” Topical Ruxolitinib may safely treat severe hair loss.
95 citations,
November 2018 in “Australasian journal of dermatology” Alopecia areata treatment varies, with no optimal method established yet.
68 citations,
November 2015 in “The Journal of Allergy and Clinical Immunology” Blocking IL-12/IL-23p40 helped reverse severe hair loss in patients.
51 citations,
December 2011 in “The Journal of Dermatology” New treatments for severe hair loss often fail, but some patients see hair regrowth with specific therapies, and treatment should be tailored to the individual's situation.
48 citations,
May 1999 in “International Journal of Dermatology” Alopecia areata is an unpredictable autoimmune hair loss condition, treated based on severity, with half of patients regrowing hair within a year without treatment.
45 citations,
January 2010 in “International journal of trichology” Topical immunotherapy, especially with DPCP, is effective for treating severe alopecia areata.
41 citations,
November 2015 in “The journal of investigative dermatology. Symposium proceedings/The Journal of investigative dermatology symposium proceedings” Diphenylcyclopropenone (DPCP) can help regrow hair in many alopecia areata patients but may cause side effects and relapses.
36 citations,
July 2007 in “Journal of Investigative Dermatology” Certain HLA class II alleles increase or decrease the risk of alopecia areata.
30 citations,
June 2017 in “Journal of cutaneous medicine and surgery” Topical ruxolitinib failed to regrow hair in a 66-year-old with alopecia areata.
30 citations,
May 2016 in “Expert Opinion on Biological Therapy” New treatments targeting immune pathways show promise for severe hair loss but need more research for safety and effectiveness.
28 citations,
December 2017 in “Journal of Investigative Dermatology Symposium Proceedings” Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.
26 citations,
July 2019 in “JAAD Case Reports” Dupilumab for atopic dermatitis may cause new or worsen existing alopecia areata.
25 citations,
March 2017 in “International Journal of Dermatology” Ruxolitinib effectively and safely regrows hair in alopecia patients.
24 citations,
March 2009 in “Archives of dermatological research” The combination of oral PUVA and corticosteroids helps regrow hair in severe alopecia areata.
22 citations,
September 2017 in “Skin appendage disorders” Ruxolitinib helped a man regrow his beard after years of hair loss.